Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis

Lupus

Volumn 19, Issue 8, 2010, Pages 965-973

  Aragon, E ^a   Chan, Y H ^b   Ng, K H ^a,b   Lau, Y W ^a   Tan, P H ^c   Yap, H K ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

cyclosporine; mycophenolate mofetil; systemic lupus erythematosus

Indexed keywords

ACICLOVIR; CEFTRIAXONE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; ENALAPRIL; HYDROXYCHLOROQUINE; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CYSTITIS; DIALYSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HELICOBACTER INFECTION; HEMATURIA; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; LABORATORY DIAGNOSIS; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; ORCHITIS; OUTCOME ASSESSMENT; PLASMAPHERESIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; LUPUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954057433     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310366855     Document Type: Article

References (30)

1. Perfumo F., Martini A. Lupus nephritis in children. Lupus 2005 ; 14: 83-88.
2. Mok CC, Mak A., Chu WP, To CH, Wong SN Long-term survival of Southern Chinese patients with systemic lupus erythematosus: A prospective study of all age-groups. Medicine 2005 ; 84: 218-224.
3. Cameron JS Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994 ; 8: 230-249.
4. Bakkaloglu A. Lupus nephropathy in children. Nephrol Dial Transplant 2001 ; 16 (Suppl 6). 126-128.
5. Pollak VE, Pirani CL, Schwartz FD The natural history of the renal manifestations of systemic lupus erythematosus.1964. J Am Soc Nephrol 1997 ; 8: 1189-1198.
6. Lee BW, Yap HK, Yip WCL, Low PS, Tay JSH, Wong HB A ten year review of systemic lupus erythematosus in Singapore children. Australian Paediatr J 1987 ; 23: 163-165.
7. Houssiau FA, Vasconcelos C., D'Cruz D., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 2004 ; 50: 3934-3940.
8. Austin 3rd HA, Klipel JH, Balow JE, et al. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986 ; 314: 614-619.
9. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000 ; 136: 243-247.
10. Chan TM, Li FK, Tsang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000 ; 343: 1156-1162.
11. Chan TM, Tse KC, Tang CS, Mok MY, Li FK Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005 ; 16: 1076-1084.
12. Ginzler EM, Dooley MA, Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 ; 353: 2219-2228.
13. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005 ; 10: 504-510.
14. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 ; 350: 971-980.
15. Appel GB, Contreras G., Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 ; 20: 1103-1112.
16. Zhu B., Chen N., Lin Y., et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007 ; 22: 1933-1942.
17. Buratti S., Szer IS, Spencer CH, Bartosh S., Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001 ; 28: 2103-2108.
18. Fujinaga S., Ohtomo Y., Hara S., et al. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol 2008 ; 23: 1877-1882.
19. Lau KK, Ault BH, Jones DP, Butani L. Induction therapy for pediatric proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 2008 ; 22: 282-288.
20. Hochberg MC Updating the American College of Rheumatology classification revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 1725.
21. Weenig JJ, D'Agati VD, Schwartz MM, et al. on behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 ; 15: 241-250.
22. Ettenger R., Cohen A., Nast C., et al. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997 ; 29: 340-341.
23. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
24. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987 ; 34: 571-590.
25. Levey AS, Eckardt KU, Tsukamoto Y., et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Outcomes (KDIGO). Kidney Int 2005 ; 67: 2089-2100.
26. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001 ; 357: 1601-1608.
27. Dostal C., Tesar V., Rychlik I., et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998 ; 7: 29-36.
28. Fu LW, Yang LY, Chen WP, Lin CY Clinical efficacy of cyclosporine A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998 ; 37: 217-221.
29. Baca V., Catalan T., Villasis-Keever M., Ramon G., Morales AM, Rodriguez-Leyva F. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus 2006 ; 15: 490-495.
30. Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008 ; 14: 931-938.